argenx SE ARGX-BE:Euronext Brussels

RT Quote | Exchange | EUR
Last | 5:36 PM CEST
337.70quote price arrow up+2.20 (+0.66%)
Volume
31,970
52 week range
271.00 - 494.10
Loading...
  • Open335.00
  • Day High337.70
  • Day Low330.30
  • Prev Close335.50
  • 52 Week High494.10
  • 52 Week High Date07/24/23
  • 52 Week Low271.00
  • 52 Week Low Date12/20/23

Key Stats

  • Market Cap21,822.38M
  • Shares Out59.19M
  • 10 Day Average Volume50,441.1
  • Dividend-
  • Dividend Yield-
  • Beta0.63
  • YTD % Change-1.69

KEY STATS

  • Open335.00
  • Day High337.70
  • Day Low330.30
  • Prev Close335.50
  • 52 Week High494.10
  • 52 Week High Date07/24/23
  • 52 Week Low271.00
  • 52 Week Low Date12/20/23
  • Market Cap21,822.38M
  • Shares Out59.19M
  • 10 Day Average Volume50,441.1
  • Dividend-
  • Dividend Yield-
  • Beta0.63
  • YTD % Change-1.69

RATIOS/PROFITABILITY

  • EPS (TTM)-5.26
  • P/E (TTM)-64.17
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On argenx SE

 

Profile

MORE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor...
Peter Verhaeghe
Non-Executive Independent Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Karen Massey
Chief Operating Officer
Karl Gubitz
Chief Financial Officer
Malini Moorthy
General Counsel
Address
Laarderhoogtweg 25
Amsterdam
1101 EB
Netherlands